Opinion|Videos|August 2, 2024
Exploring Screening and Real-World Use of Teplizumab: Practical Insights and Clinical Experiences
Experts on type 1 diabetes discuss the availability of local medical facilities that offer teplizumab screening and evaluation services for individuals at risk of progression of disease.
Advertisement
Episodes in this series
The following is a summary of the video transcript and has been edited for length and clarity.
Goldman: In terms of where infusions are being done, where are you sending your patients?
Shenkman: Right now, we're using a couple of local infusion centers. We are also exploring other options, like either home health or partial home health, where the patient starts treatment in an infusion center for the first few days to be monitored, and then the remainder is done through home health. A lot depends on whether there is space available 14 days in a row.
Advertisement
Related to this article
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Advertisement
Advertisement